Board approves USD 4M infusion in Dubai arm, files Q2 results, plant update
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q2 FY26 results (standalone PAT Rs 19.49 lakh, consolidated PAT Rs 20.90 lakh) and equity infusion up to USD 4 million (around Rs 33 crore) in wholly owned subsidiary Balaxi Global FZCO Dubai for expansion. Subsidiary recently renamed from Balaxi Global DMCC. Also noted progress at Jadcherla formulation plant - setup complete, test license obtained, Paracetamol and Piroxicam batches produced, GMP audit prep underway.
Capital infusion supports overseas expansion; plant progress signals future growth though Q2 consolidated profits remained thin.